GERN - Geron Corp Market Cap to Sales Volume

Corporate company logo of Geron Corp. (GERN)

Geron Corporation (GERN) maintains pricing power for Rytelo due to the drug's uniqueness in treating MDS. The historical P/S level visualizes this market dynamic, where the value 2.90 serves as the baseline valuation metric. The company is implementing breakthrough telomerase inhibitors to combat tumor immortality. Meanwhile, the humanitarian status of these developments minimizes external geopolitical risks and ensures operational stability.

Geron Corp. (GERN) - Price-to-Revenue Ratio from 07/04/2022 to 11/13/2026

Metric breakdowns and analytics for Geron Corp. (GERN)

- stock value and consensus price forecast:
Stock Price geron.com|GERN - Consensus Target
- market capitalization statistics:
Market Value Geron Corp.|GERN - Enterprise Value
- book capitalization information:
Share Book Value Geron|GERN - Company Book Value|Market-to-Book Ratio geron.com|GERN - Aggregate Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Geron Corporation|GERN - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Geron Bio|GERN - Company Debts|Debts to Net Assets Geron Corp.|GERN - Company Long-Term Debts|Short-Term Indebtedness Geron|Immediate Liquidity geron.com
- earnings and valuation multiples indicators:
GERN - Company Net Income|Expected Net Income Geron Corporation|GERN - Price to Earnings Ratio|Projected Price to Earnings Ratio Geron Corp|GERN - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Geron Corp.|GERN - Operating profit before deduction of amortization|Earnings per share for the trailing year Geron|GERN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months geron.com|GERN - Earnings per share growth in current year|Expected net earnings per share growth next year Geron Corporation
- total revenue and sales volume data:
GERN - Company Revenue|Company Future Revenue geron.com|GERN - Price-to-Revenue Ratio|Future Price to Revenue Geron Corp.
Fundamental company analysis:GERN, geron.com
Finished products of Geron Corporation

By utilizing an asset-light model with outsourced drug production, Geron Corporation minimizes capital expenditures, making revenue the key basis for business valuation. By analyzing the company's P/S ratio dynamics, an investor determines the market value of one dollar of sales, assessing the extent of the premium paid for future R&D success and the resilience of the capitalization to potential logistical disruptions from partners.

Competing companies

P/S Multiple nanobiotix.com (NBTX)|Bicycle Therapeutics plc - Market Cap to Revenue|Market Cap to Sales Volume CTMX (CytomX Pharma)|Perspective Therapeutics Inc - P/S Multiple|Price-to-Sales Ratio GNLX|Molecular Partners AG (MOLN) - Price-to-Revenue Ratio|Price to Sales Oncolytics Biotech (ONCY)|Price-to-Revenue Ratio Lisata Therapeutics Inc.|MBRX: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Galera Therapeutics (GRTX)|Market Cap to Revenue Molecular Templates Corporation MTEM